skip to Main Content

ZOE HARCOMBE c | PCSK9 inhibitors…lower LDL, but RAISE DEATH RATES
presents episode 1039 | Dr. Zoe Harcombe
Low Carb All Stars podcast

2017 clinical trial of drug, Evolocumab [PCSK9 inhibitor] -2 groups
-intervention: had their cholesterrol lowered
-placebo: cholesterol is higher

Key point:
these drugs do low cholesterol, but
is this a clinical benefit?

-placebo: coronary revascularizations were 27% HIGHER
-easy to recommend them by doctors concerned about LDL
-this subjective part has large influence on total study data

“CVD deaths & all-cause deaths were HIGHER in the treatment
group. The HRs were not statistically significant, but the

“As well as an absent mortality benefit…
the Amgen trial, which used participants in a range of countries,
showed evocolumab did not benefit the European patients.”


Original youtube:

This site will never use corruptible, epidemiological survey research as causal science.
For each short/sharable video, the original Youtube links are provided

None of this content is intended to be individual, personalized medical advice.

We hope you find value for yourself in these short videos &
find them easy to share with loved ones!

The DoctorsToTrust videos are for general informational purposes only
and do not constitute the practice of medicine, nursing or other
professional health care services, including the giving of medical advice,
and no doctor/patient relationship is formed. The use of information on this podcast
or materials linked from this podcast is at the user’s own risk.
The content of this podcast is not intended to be a substitute for
professional medical advice, diagnosis, or treatment. Users should not disregard or
delay in obtaining medical advice for any medical condition they may have and
should seek the assistance of their health care professionals for any such conditions.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *